Financhill
Back

CNS Pharmaceuticals Quote, Financials, Valuation and Earnings

Master the Market: The Formula for a 96.3% Win Rate Revealed!

Act now!
Sell
23

CNSP
CNS Pharmaceuticals

Last Price:
0.21
Seasonality Move:
-16.83%

7 Day Trial

ALL ACCESS PASS

$ 7

Unlock the Secret to Earning Monthly Income!

Limited spots act swiftly

CNS Pharmaceuticals Price Quote

$0.21
-0.01 (-2.55%)
(Updated: May 3, 2024 at 1:50 PM ET)

CNS Pharmaceuticals Key Stats

Sell
23
CNS Pharmaceuticals (CNSP) is a Sell

Day range:
$0.21 - $0.23
52-week range:
$0.19 - $2.98
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0%

Volume:
111.4K
Avg. volume:
162.6K
1-year change:
-85.82%
Market cap:
$2.3M
Revenue:
$0
EPS:
$-5.57

How Much Does CNS Pharmaceuticals Make?

Data Unavailable

Is CNS Pharmaceuticals Growing As A Company?

Data Unavailable

CNS Pharmaceuticals Stock Price Performance

What Is CNS Pharmaceuticals 52-Week High & Low?

CNS Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy CNS Pharmaceuticals?

Is CNS Pharmaceuticals Cash Flow Positive?

  • What Is CNSP Cash Flow From Operations?
    Cash flow from operations (TTM) is -$14.1M
  • What Is CNS Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $4.6M
  • What Is CNS Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

CNS Pharmaceuticals Return On Invested Capital

Data Unavailable

CNS Pharmaceuticals Earnings Date & Stock Price

CNS Pharmaceuticals Competitors

CNS Pharmaceuticals Dividend Yield

Data Unavailable

CNS Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 30.00
Upside from Last Price: 13821.13%

Major Shareholders

  • How many CNSP shares are owned by institutional investors?
    388.1K CNSP shares are owned by institutional investors
  • How many CNSP shares are owned by insiders?
    406.7K CNSP shares are owned by insiders